Post Marketing Surveillance of inj. SepsivacÂ® (Mycobacterium w) to evaluate safety and efficacy in combination with standard therapy in gram negative bacterial sepsis

Cadila Pharmaceuticals Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年4月3日

试验速览

暂无简介。

•Sepsis patients with gram negative infection having age between 18 to 65 years (Both inclusive) where, Sepsis is defined as suspected or documented infection and an acute increase of â©¾2 SOFA points.5 AND having at least one of the following:
•Source of Gram negative sepsis presumed to be originating from these sources (gastrointestinal, hepatobiliary, genitourinary tract, pulmonary, neurological) or
•Documented by typical clinical signs and symptoms and confirmed by blood culture and/or histology or
•Documented by typical clinical signs and symptoms and confirmed by CSF culture/tissue culture and/or histology or
•Positive culture or histology confirmation or any other investigation deemed necessary must be obtained at the time of enrolment and prior to the first dose of study medication.

•History of allergic reactions attributed to Mycobacterium w (Heat Killed) injection or any of the excipients in the formulation.
•Pregnant and Lactating women.
•Individuals with generalized septic skin conditions (if eczema exists, a site should be chosen that is free from skin lesions).
•Patient with chronic debilitating condition other than the proposed indication.

发起方